Histone deacetylase inhibitor potentiates anticancer effect of docetaxel via modulation of Bcl-2 family proteins and tubulin in hormone refractory prostate cancer cells.
Hwang
Jung Jin
JJ
Institute for Innovative Cancer Research, Department of Urology, University of Ulsan College of Medicine, Asan Medical Center, Seoul, Korea.
Kim
Yong Sook
YS
Kim
Mi Joung
MJ
Kim
Dong Eun
DE
Jeong
In Gab
IG
Kim
Choung-Soo
CS
D000818:Animals; D017209:Apoptosis / Q000187:drug effects; D000077143:Docetaxel; D004357:Drug Synergism; D056572:Histone Deacetylase Inhibitors / Q000494:pharmacology* / Q000627:therapeutic use*; D006801:Humans; D008297:Male; D051379:Mice; D008807:Mice, Inbred BALB C; D011471:Prostatic Neoplasms / Q000188:drug therapy*; D019253:Proto-Oncogene Proteins c-bcl-2 / Q000187:drug effects*; D043823:Taxoids / Q000627:therapeutic use*; D014404:Tubulin / Q000187:drug effects*; D014407:Tumor Cells, Cultured
D056572:Histone Deacetylase Inhibitors; D019253:Proto-Oncogene Proteins c-bcl-2; D043823:Taxoids; D014404:Tubulin; D000077143:Docetaxel